A Study of IBI363 in Subjects With Advanced Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

June 6, 2025

Study Completion Date

July 31, 2026

Conditions
Melanoma
Interventions
BIOLOGICAL

IBI363

IBI363 monotherapy

Trial Locations (12)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Peking University Cancer Hospital & Institute, Beijing, China,, Beijing

130012

RECRUITING

Jilin Cancer Hospital, Changchun

130021

RECRUITING

The first hospital of Jilin University, Changchun

210000

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

250012

RECRUITING

Qilu Hospital of Shandong university, Jinan

330052

RECRUITING

The first affiliated hospital of Nanchang university, Nanchang

350000

RECRUITING

Fujian Cancer Hospital, Fuzhou

410031

RECRUITING

Hunan Cancer Hospital, Changsha

450044

RECRUITING

The Third people's hospital of Zhengzhou, Zhengzhou

650118

RECRUITING

Yunan Cancer Hospital, Kunming

030032

RECRUITING

Shanxi Bethune Hospital, Taiyuan

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY